Spectral Medical Full Year 2023 Earnings: Misses Expectations
Spectral Medical (TSE:EDT) Full Year 2023 Results
Key Financial Results
Revenue: CA$1.60m (down 4.1% from FY 2022).
Net loss: CA$15.5m (loss widened by 104% from FY 2022).
CA$0.056 loss per share (further deteriorated from CA$0.028 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Spectral Medical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) also missed analyst estimates by 50%.
In the last 12 months, the only revenue segment was Spectral Medical Inc. contributing CA$1.60m. Notably, cost of sales worth CA$936.0k amounted to 59% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CA$11.3m (70% of total expenses). Explore how EDT's revenue and expenses shape its earnings.
The company's shares are up 2.2% from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for Spectral Medical (3 shouldn't be ignored!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.